Market Cap
$15.0B
ASND
Ascendis Pharma A/S
$227.87 ▲ +0.25%
Prev close $227.31Market cap$15.0B
ConsensusStrong Buy
12-mo target$307.36 (+34.9%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)33 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ASND right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (96%)
Inst. Holders
50 funds
Inst. Value
$9.0B
Inst. Activity
1 buys / 33 sells
Insider Activity
$777.1K buy / $5.5M sell
Insider Net $
-$4.7M
SEC Reports
20
Press Releases
6
Price chart 30d -16.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 short_volume
Short Volume: ASND — 58.0% short (0.4M / 0.6M)
Short: 363,017 | Exempt: 0 | TRF Vol: 626,155 | Short Ratio: 58.0% | Off-exchange volume (dark pool
Sep 8, 2026 Insider
Bodenhoff Mads sold 3,000 shares
SVP & PAO @ $270.19 ($810.6K)
Sep 8, 2026 Insider
Sep 2, 2026 SEC Bodenhoff Mads acquired via exercise 3,000 shares
SVP & PAO @ $110.00 ($330.0K)
HC Wainwright & Co. initiates ASND to Buy — PT $345 (+31%)
ANALYST-UPGRADE — Impact 4/10
Sep 2, 2026 Insider
Aug 19, 2026 SEC HOLTUG LARS sold 236 shares
Director @ $264.13 ($62.3K)
BMO Capital initiates ASND to Outperform — PT $319 (+28%)
ANALYST-UPGRADE — Impact 4/10
Ascendis Pharma released positive Phase 2 COACH trial data showing its TransCon CNP + TransCon hGH combination therapy m
Impact 7/10
Aug 3, 2026 Event
YORVIPATH
Supplemental Approval — Labeling — PALOPEGTERIPARATIDE — SOLUTION — SUBCUTANEOUS
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
96% rate it Buy or better · 28 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 25, 2026 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Sep 15, 2026 | Raymond James | DOWNGRADE | Outperform | 54% |
| Sep 2, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
| Sep 1, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Sep 1, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Aug 31, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| Aug 31, 2026 | Jefferies | MAINTAIN | Buy | 53% |
| Aug 31, 2026 | Stifel | MAINTAIN | Buy | 54% |
| Aug 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 27, 2026 | HC Wainwright & Co. | INITIATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 12 | 15 | 1 | 0 | 0 | 96% | |
| Aug 1, 2026 | 12 | 13 | 1 | 0 | 0 | 96% | |
| Jul 1, 2026 | 12 | 13 | 1 | 0 | 0 | 96% | |
| Jun 1, 2026 | 12 | 13 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% |
Price targets
Where 20 covering analysts think ASND trades over the next 12 months.
$307.36 +34.9% upside Strong Buy
Current$227.87 Low$263.28 Median$313.65 High$351.29 20 analysts
$263.28$351.29
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 13 bullish, 0 bearish, 0 mixed, 7 neutral · avg impact 5.0/10.Plus 6 press releases.
BULLISHANALYST-UPGRADE3/10
Citigroup initiates ASND to Buy — PT $355 (+44.7%)
May 19, 2026
BULLISHANALYST-UPGRADE4/10
HC Wainwright & Co. initiates ASND to Buy — PT $345 (+31%)
Sep 2, 2026
BULLISHANALYST-UPGRADE4/10
BMO Capital initiates ASND to Outperform — PT $319 (+28%)
Aug 19, 2026
NEUTRALCLUSTER2/10
Two Ascendis Pharma insiders sold a combined $873K in shares over a 7-day window, with the bulk ($81
Sep 10, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
short_volume
Short Volume: ASND — 58.0% short (0.4M / 0.6M)
Short: 363,017 | Exempt: 0 | TRF Vol: 626,155 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: ASND — 61.7% short (0.3M / 0.5M)
Short: 335,668 | Exempt: 7 | TRF Vol: 544,236 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: ASND — 58.0% short (0.3M / 0.5M)
Short: 295,771 | Exempt: 52 | TRF Vol: 509,697 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: ASND — 63.1% short (0.9M / 1.4M)
Short: 884,057 | Exempt: 10,917 | TRF Vol: 1,400,247 | Short Ratio: 63.1% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
buyback
Ascendis Announces Planned $400 Million Share Repurchase Program
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.94 | $0.64–$1.09 | — | -1.4% | 0↑ 2↓ | $0.4B | 3 |
| Next Q | $1.16 | $0.61–$1.51 | — | -1.7% | 0↑ 2↓ | $0.4B | 3 |
| Current FY | $12.79 | $3.61–$18.69 | — | +12.8% | 1↑ 2↓ | $1.4B | 5 |
| Next FY | $9.62 | $6.26–$16.16 | -24.8% | +17.9% | 1↑ 2↓ | $2.0B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.937 | — |
| 7d ago | $0.950 | -0.013 |
| 30d ago | $0.950 | -0.013 |
| 60d ago | $1.317 | -0.380 |
| 90d ago | $1.195 | -0.258 |
Institutional ownership
Which big funds own ASND (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $9.0B total value (39,514,593 shares) as of 2026-Q1. Top holders: RA, Avoro, FMR. Net buying activity: 9 institutions added/increased vs 7 reduced.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10,281,496 | $2.4B | 26.0% | EXIT -100.0% |
| Avoro Capital Advisors LLC | 5,062,500 | $1.2B | 12.8% | EXIT -100.0% |
| FMR LLC | 3,876,601 | $886.7M | 9.8% | EXIT -100.0% |
| Artisan Partners Limited Partnership | 3,230,188 | $738.8M | 8.2% | EXIT -100.0% |
| FRANKLIN RESOURCES INC | 2,051,948 | $469.3M | 5.2% | — |
| Capital International Investors | 1,958,843 | $448.0M | 5.0% | EXIT -100.0% |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1,860,669 | $425.6M | 4.7% | EXIT -100.0% |
| WELLINGTON MANAGEMENT GROUP LLP | 1,757,633 | $402.0M | 4.5% | EXIT -100.0% |
| Capital World Investors | 900,517 | $206.0M | 2.3% | EXIT -100.0% |
| BlackRock, Inc. | 661,054 | $151.2M | 1.7% | EXIT -100.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | DOUBLED | 87,334 | 513,969 | +488.5% | $137.1M |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | EXIT | 58,859 | 0 | -100.0% | $0.00 |
| Avoro Capital Advisors LLC | EXIT | 5,062,500 | 0 | -100.0% | $0.00 |
| RA CAPITAL MANAGEMENT, L.P. | EXIT | 10,281,496 | 0 | -100.0% | $0.00 |
| Trexquant Investment LP | EXIT | 65,517 | 0 | -100.0% | $0.00 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | EXIT | 114,275 | 0 | -100.0% | $0.00 |
| FRED ALGER MANAGEMENT, LLC | EXIT | 304,896 | 0 | -100.0% | $0.00 |
| Woodline Partners LP | EXIT | 102,469 | 0 | -100.0% | $0.00 |
| Polar Capital Holdings Plc | EXIT | 651,712 | 0 | -100.0% | $0.00 |
| Artisan Partners Limited Partnership | EXIT | 3,230,188 | 0 | -100.0% | $0.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 15 transactions. Net -$4.7M — $777.1K bought, $5.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Bodenhoff Mads | SVP & PAO | SELL | 3,000 | $270.19 | $810.6K |
| Sep 8, 2026 | Bodenhoff Mads | SVP & PAO | EXERCISE | 3,000 | $110.00 | $330.0K |
| Sep 2, 2026 | HOLTUG LARS | Director | SELL | 236 | $264.13 | $62.3K |
| Aug 14, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 1,100 | $245.85 | $270.4K |
| Aug 14, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 900 | $246.91 | $222.2K |
| Jun 2, 2026 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | BUY | 100 | $219.00 | $21.9K |
| May 29, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 100 | $223.50 | $22.4K |
| May 29, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 200 | $222.30 | $44.5K |
| May 29, 2026 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | BUY | 250 | $223.32 | $55.8K |
| May 29, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 200 | $223.76 | $44.8K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ASND.
Shares short
3,961,960
Settlement Sep 15, 2026
Change vs prior
-5.7%
Semi-monthly cycle
Days to cover
4.9
At avg daily volume
Of shares outstanding
≈6.0%
Estimate — not % of float
All ASND filing & press-release reports (29)
- Citigroup initiates ASND to Buy — PT $355 (+44.7%)May 19, 2026
- HC Wainwright & Co. initiates ASND to Buy — PT $345 (+31%)Sep 2, 2026
- BMO Capital initiates ASND to Outperform — PT $319 (+28%)Aug 19, 2026
- CLUSTER reportSep 10, 2026
- 6-K reportAug 31, 2026
- INSIDER-BUY reportAug 19, 2026
- 6-K reportAug 13, 2026
- PRESS-RELEASE reportAug 13, 2026
- 6-K reportAug 6, 2026
- PRESS-RELEASE reportAug 6, 2026
- 6-K reportJul 15, 2026
- 6-K reportJul 3, 2026
- 6-K reportJul 3, 2026
- PRESS-RELEASE reportJun 30, 2026
- 6-K reportJun 17, 2026
- 6-K reportJun 15, 2026
- PRESS-RELEASE reportJun 13, 2026
- 6-K reportJun 12, 2026
- CLUSTER reportJun 2, 2026
- 6-K reportMay 7, 2026
- 6-K reportMay 7, 2026
- PRESS-RELEASE reportMay 6, 2026
- 6-K reportApr 21, 2026
- 6-K reportApr 8, 2026
- 6-K reportApr 8, 2026
- PRESS-RELEASE reportApr 8, 2026
- 6-K reportApr 7, 2026
- 3 reportApr 1, 2026
- PRESS-RELEASE reportMar 17, 2026